Aktienanalyse zu TherapeuticsMD Inc (TXMD)TXMDTherapeuticsMD Inc

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

TherapeuticsMD Inc (TXMD) is a good buy right now due to its recent price increase of 7.77% over the last five days and a strong forward P/E ratio of 2.33, suggesting undervaluation relative to future earnings. Additionally, the stock has shown a remarkable 109.43% increase over the past year, indicating strong momentum. However, a risk to consider is the negative net income reported in Q2 2026, which was $0, highlighting ongoing profitability challenges.

9 analysts cover TXMD: 8 rate it Buy, 1 Hold and 0 Sell.